Telli Health Announces Verizon Certification, Becomes 1st Medical IoT Device Company to Operate on Their Cellular Network

All Telli Health Devices Can Now Use Verizon Cellular Network, Further Boosting Reliability, Accessibility, and Ease of Use for Patients Everywhere

Telli Health today announced that it has been certified by Verizon, allowing all of its devices to operate on Verizon, America’s largest and most reliable cellular network. With Verizon’s vast cellular footprint, patients can take a reading from anywhere and know it will be sent instantly to their provider. Telli Health’s connected care devices are the first and only Verizon-certified devices in the United States.

The remote patient monitoring (RPM) industry has long suffered from deficient reliability in transmitting patient readings, as well as the ability to take readings from anywhere. Being Verizon certified will improve this, and for healthcare providers and RPM companies, this means increased patient adherence—a primary goal for both.

Telli Health’s devices use SIM technology that connects to all major cellular carriers in the United States, including AT&T and T-Mobile/Sprint, in addition to Verizon. Globally, coverage includes over 650 cellular carriers in 191 countries.

Jeff Bartzen, Sales Executive at Telli Health, commented, “Our competitors typically use Bluetooth and antiquated third-party technology for their remote care medical devices. This presents problems ranging from connectivity issues to requiring cell phones and difficult pairing for an aging population. Our competitors are only now starting to use cellular-connected devices—which is easier and the way of the future—but they only work on either AT&T or T-Mobile. I am very pleased that we have partnered with Verizon to deliver value-based in-home healthcare to more people than ever before, securing Telli Health as the premier destination for reliable, accurate, accessible, and easy-to-use connected care medical devices. Physicians can trust 4G cellular technology as a tremendous improvement over current devices plagued by connectivity issues and unreliability.”

According to a Telli Health case study with one of the industry’s leading RPM providers, from 2018 through 2020, options for cellular-connection blood pressure and blood glucose devices were very limited despite demand. From high rates of data transmission failures to issues related to accuracy and ease of use, the devices in the marketplace were not up to industry standards. Telli Health entered in 2021, offering 4G cellular-enabled devices that directly addressed these specific issues. Telli Health blood pressure monitors and blood glucose meters consistently delivered accurate and reliable readings. The RPM company reported on average a 10 mmHg reduction in both systolic and diastolic blood pressures, with some patients seeing as much as 30 mmHg reductions. Also observed were increased patient satisfaction, a 50% reduction in patient churn due to accuracy, consistency, and reliability of data transmission using Telli Health devices, and an overall 30% improvement in daily compliance and successful transmissions in which providers received substantially more patient readings. Now being Verizon certified, Telli Health looks forward to expanding these successes with the world’s first touchless 4G Thermometer, 4G Weight Scale (December 2021), and the world’s first 4G Pulse Oximeter (December 2021).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”